From Financial Modeling Prep: 2025-04-23 13:55:00

Boston Scientific (NYSE:BSX) exceeded Q1 earnings and revenue expectations, reporting adjusted earnings of $0.75 per share and revenue of $4.66 billion, up 20.9% YoY. Cardiovascular sales surged 26.2% to $3.09 billion, while MedSurg revenue rose 11.7% to $1.58 billion, driving the company’s strong performance.

Following the robust Q1 results, Boston Scientific raised its full-year 2025 earnings guidance to $2.87 to $2.94 per share, up from $2.80 to $2.87. The company anticipates organic revenue growth between 12% and 14% for the year, reflecting sustained momentum across its product lines and strong demand for heart and vascular treatments.

For Q2, Boston Scientific projects organic revenue growth of 13% to 15% and adjusted earnings per share between $0.71 and $0.73, underscoring confidence in its growth trajectory and operational capabilities. Shares of Boston Scientific rose over 5% intra-day following the earnings announcement, signaling investor optimism in the company’s outlook.



Read more at Financial Modeling Prep:: Boston Scientific Surges 5% After Blowout Q1